Interleukin‑23 (IL‑23, also known as IL23A), is an important proinflammatory cytokine whose role in the development and progression of tumors remains controversial. The present study on IL‑23 focused on its impact on the tumor microenvironment. Existing studies on its direct role on tumor cells are limited. Previously, we reported that the expression level of IL‑23 in human bladder urothelial carcinoma was significantly higher than that in adjacent tissues as determined by immunohistochemistry. In this study, we further validated the results of immunohistochemistry using the Oncomine database and we found that IL23A expression in non‑muscle invasive bladder urothelial carcinoma (NMIBC) was significantly higher than that in muscle invasive bladder urothelial carcinoma (MIBC). Expression of IL23A was negatively correlated with the clinical stage of bladder urothelial carcinoma and had a positive correlation with prognosis. In vitro experiments revealed that different concentrations of IL‑23 had different effects on T24 cells. A low concentration of 20 ng/ml IL‑23 promoted T24 cell proliferation, migration, invasion and EMT transformation, while a high concentration of 40 ng/ml IL‑23 inhibited these functions. These results indicated that IL‑23 plays a dual role in the progression of bladder cancer. Low concentrations of IL‑23 promote bladder tumor progression, while high concentrations of IL‑23 have the opposite effect.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3892/or.2018.6775 | DOI Listing |
Objective: To evaluate the correlation between ATP-binding cassette (ABC) transporter expression and therapeutic efficacy of enfortumab vedotin (EV), an antibody-drug conjugate targeting Nectin-4, in urothelial cancer, as only a few studies have been conducted on this topic.
Patients And Methods: This retrospective study included 20 patients with metastatic urothelial carcinoma (mUC), including bladder and upper urinary tract cancers, who were treated with EV at Dokkyo Medical University Hospital between 2022 and 2024. Immunohistochemical staining was performed on formalin-fixed, paraffin-embedded tissue samples.
Clin Chim Acta
January 2025
Department of Urology, The People's Hospital of Qingyang City/Qingyang Hospital of the Second Hospital of Lanzhou University, Qingyang 745000 China. Electronic address:
Background: Urothelial carcinoma (UC) is a common malignancy worldwide. Aberrant DNA methylation is implicated in UC carcinogenesis. This study sought to delineate the DNA methylation landscape in UC and identify DNA methylation-based biomarkers for early detection of UC.
View Article and Find Full Text PDFWiad Lek
January 2025
DEPARTMENT OF GENERAL PATHOLOGY AND FORENSIC MEDICINE, COLLEGE OF MEDICINE, UNIVERSITY OF KUFA, KUFA, IRAQ.
Objective: Aim: To evaluate the expression levels of SOX-10 in tissues of bladder tumor and to prove the correlation between SOX-10 expression and clinicopathological characteristics of bladder tumors, including patient age, sex, tumor grade, and muscle invasion.
Patients And Methods: Materials and Methods: Forty formalin fixed paraffin embedded FFPE tissue blocks gathered by transurethral resection of bladder tumor are collected from teaching hospitals at Al-Najaf governorate. Those blocks were stained by hematoxylin and eosin.
Wiad Lek
January 2025
DEPARTMENT OF GENERAL PATHOLOGY AND FORENSIC MEDICINE, COLLAGE OF MEDICINE, UNIVERSITY OF KUFA, KUFA, IRAQ.
Objective: Aim: To analyze expression levels of GATA-3 in bladder tumor tissues and to prove a relation between expression of GATA-3 and clinicopathological characteristics of bladder tumors, including patient age, sex, tumor grade, and muscle invasion.
Patients And Methods: Materials and Methods: Forty formalin fixed paraffin embedded (FFPE) tissue blocks obtained from bladder tumor by transurethral resection are collected from teaching hospitals at Al-Najaf governorate. Those blocks are stained by using hematoxylin and eosin stain.
Biol Proced Online
January 2025
Department of Urology, Tianjin Union Medical Center, No. 190 Jie-yuan Road, Hong-qiao District, Tianjin, China.
Background: HER2 expression has been confirmed to be associated with bladder cancer aggressiveness. Anti-HER2 RC48-ADC is approved in China for the treatment of patients with advanced urothelial carcinoma with failed chemotherapy who are HER2 positive (IHC 2 + or 3 +). The discovery of HER2 positivity in urothelial carcinoma and the development of anti-HER2 drugs have brought new hope for bladder preservation treatment in MIBC.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!